
DermTech, Inc.
- Jurisdiction
United States - ISIN
US24984K1051 (DMTK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. Read full profile
Fundamentals
- Net revenue
€13.36M - Gross margin
8.5% - EBIT
-€77.53M - EBIT margin
-580.3% - Net income
-€76.45M - Net margin
-572.2%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: February 29, 2024 (Q4 2023)